Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Experimental and Applied Biomedical Research (EABR) is Scopus-indexed (Q3, CiteScore 0.6). Published by Sciendo.
Checked against the index lists dated .
ISSN 2956-0454Verify ISSN ↗2956-2090Verify ISSN ↗
Publisher: Sciendo
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (all) | 469 / 669 | 29th | Q3 |
| Biochemistry, Genetics and Molecular Biology (all) | 210 / 223 | 6th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q3, CiteScore 0.6.
Experimental and Applied Biomedical Research (EABR) is Q3 in Medicine (all) (rank 469 of 669) and Q4 in Biochemistry, Genetics and Molecular Biology (all) (rank 210 of 223), by CiteScore 2025.
Experimental and Applied Biomedical Research (EABR) is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.6, quartile Q3, 29th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.134, quartile Q4, with an H-index of 12.
Experimental and Applied Biomedical Research (EABR) is published by Sciendo. Its print ISSN is 2956-0454 and its online ISSN is 2956-2090.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Experimental and Applied Biomedical Research (EABR) has an h-index of 5 and a 2-year mean of 0.23 citations per paper (OpenAlex). Its Scopus CiteScore is 0.6, quartile Q3. On 2-year citations it ranks #463 of 646 Scopus journals in Medicine (all).
Experimental and Applied Biomedical Research (EABR) published 34 papers in 2025; its busiest recent year was 2023 with 40. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2023–2026), authors are most often from Serbia (75.7%), India (4.3%) and Russia (4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.